Bolt Biotherapeutics (BOLT) AI Stock Analysis

• Market Cap: $11.32M
• Dividend Yield: N/A
• Average Volume (3M): 29.18K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.44
• Revenue Growth: -46.88%
• EPS Growth: 34.83%
• Country: US
• Employees: 52
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -3.72
• Shares Outstanding: 1,919,441
• 10 Day Avg. Volume: 31,146
• 30 Day Avg. Volume: 29,181
• PEG Ratio: 0.66
• Price to Book (P/B): 7.14
• Price to Sales (P/S): 53.13
• P/FCF Ratio: -6.66
• Enterprise Value/Market Cap: 1.52
• Enterprise Value/Revenue: 3.30
• Enterprise Value/Gross Profit: 3.83
• Enterprise Value/Ebitda: -0.40
• 1Y Price Target: $41.00
• Price Target Upside: 594.92% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: $7.00 ▲(18.64% Upside)

The score is primarily held down by weak financial performance, driven by large ongoing losses, heavy cash burn, and rising leverage as equity declines. Technicals provide a partial offset with improving short-to-medium term momentum, but the longer-term trend remains mixed. Valuation is not supportive because profitability is negative and there is no dividend yield data.

Positive Factors

Boltbody targeted delivery platform

The Boltbody platform provides a structural competitive advantage by concentrating innate-immune agonists at tumors, potentially improving efficacy and reducing systemic toxicity. This modality-level differentiation supports durable IP, licensing appeal, and strategic partnering opportunities over months to years.

Clinical-stage pipeline (lead BDC-1001)

Having clinical-stage assets like BDC-1001 shifts value creation toward data-driven de-risking events (trials, readouts). Successful readouts can materially derisk programs and unlock milestone/licensing revenue, making the company attractive to partners and enabling non-dilutive financing pathways long term.

Positive revenue growth trend

Although revenue is small, consistent TTM growth indicates initial commercial, collaboration, or service traction. Sustained revenue expansion can validate translational progress, diversify cash sources, and reduce reliance on capital markets, improving durability of operations over the next several quarters.

Negative Factors

High and persistent cash burn

Large negative operating and free cash flow signals ongoing financing dependence; rapid cash depletion threatens trial timelines and forces equity/debt raises. Repeated fundraising risks dilution and compresses optionality, leaving strategic choices constrained absent partnership or clinical success.

Deep ongoing losses

Substantial negative EBIT and net losses reflect lack of sustainable profitability and long runway to commercial breakeven. Continued operating deficits erode retained capital, limit reinvestment, and increase dependence on external funding, amplifying execution risk for development programs.

Rising leverage and weakened equity base

Higher leverage and shrinking equity reduce financial flexibility and increase refinancing risk. With limited cash generation, elevated debt burdens constrain the company's ability to fund trials internally and weaken negotiating power for partnerships, raising dilution and downside risk.

Bolt Biotherapeutics Business Overview & Revenue Model

Company Description

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.

How the Company Makes Money

Bolt Biotherapeutics generates revenue primarily through the advancement of its proprietary drug candidates and strategic collaborations with pharmaceutical companies. The company's revenue model includes potential milestone payments from partnerships, royalties on future product sales, and funding from government grants and research institutions. Significant partnerships with larger biotech and pharmaceutical firms provide Bolt with financial support and resources to accelerate its research and development efforts, while also enabling shared risk in the development of new therapies. As Bolt progresses its clinical trials and achieves development milestones, it has the potential to unlock additional revenue streams through licensing agreements or partnerships.

Bolt Biotherapeutics Financial Statement Overview

Summary

Financial profile is weak: the company remains deeply unprofitable (TTM EBIT -$44.7M; net loss -$42.7M) with significant ongoing cash burn (TTM operating cash flow -$47.1M; free cash flow -$47.2M). Revenue growth exists (TTM revenue $5.2M, ~24.7% growth) but is small relative to losses. Balance sheet leverage has increased as equity has weakened (debt ~$23.6M vs equity ~$32.1M; debt-to-equity ~0.73), increasing financing and dilution risk if burn persists.

Income Statement

Bolt Biotherapeutics remains deeply unprofitable despite modest top-line expansion. Revenue in TTM (Trailing-Twelve-Months) is $5.2M with ~24.7% growth, but losses are substantial (EBIT of -$44.7M; net income of -$42.7M), resulting in very negative profitability. Gross profit is positive in TTM, but margins and earnings have been volatile across annual periods, and the business has not yet demonstrated a path to sustainable profitability.

Balance Sheet

The balance sheet shows moderate leverage but weakening capitalization over time. In TTM (Trailing-Twelve-Months), total debt is ~$23.6M versus equity of ~$32.1M (debt-to-equity ~0.73), which is meaningfully higher leverage than prior years when equity was stronger. Total assets are ~$65.1M, and returns on equity are sharply negative, reflecting continued losses and a shrinking equity base—raising financial flexibility and dilution/financing risk if cash burn persists.

Cash Flow

Cash generation is a key concern. TTM (Trailing-Twelve-Months) operating cash flow is -$47.1M and free cash flow is -$47.2M, with free cash flow trending worse versus the prior period (negative growth). While cash outflow broadly tracks accounting losses (free cash flow roughly in line with net loss), the scale of ongoing cash burn implies continued dependence on external funding.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.20M	7.69M	7.88M	5.73M	1.26M	231.00K
Gross Profit	4.48M	7.69M	-53.67M	-67.39M	-74.39M	-40.13M
EBITDA	-42.94M	-66.45M	-74.34M	-88.66M	-91.59M	-48.57M
Net Income	-42.68M	-63.12M	-69.20M	-88.10M	-98.59M	-60.73M
Balance Sheet
Total Assets	65.05M	99.63M	159.78M	227.81M	307.72M	46.54M
Cash, Cash Equivalents and Short-Term Investments	31.91M	47.32M	102.19M	168.89M	186.22M	22.84M
Total Debt	23.59M	25.21M	20.22M	22.61M	24.36M	10.88M
Total Liabilities	32.95M	42.43M	47.04M	56.30M	57.60M	151.49M
Stockholders Equity	32.10M	57.20M	112.74M	171.51M	250.12M	-104.95M
Cash Flow
Free Cash Flow	-47.20M	-61.33M	-69.73M	-78.46M	-59.40M	-50.57M
Operating Cash Flow	-47.12M	-61.29M	-69.53M	-76.50M	-57.07M	-47.31M
Investing Cash Flow	55.46M	57.58M	71.04M	57.86M	-232.20M	-20.59M
Financing Cash Flow	43.00K	108.00K	253.00K	503.00K	311.11M	39.60M

Bolt Biotherapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 5.90
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BOLT, the sentiment is Neutral. The current price of 5.9 is below the 20-day moving average (MA) of 6.22, above the 50-day MA of 5.64, and above the 200-day MA of 5.81, indicating a neutral trend. The MACD of 0.23 indicates Positive momentum. The RSI at 47.18 is Neutral, neither overbought nor oversold. The STOCH value of 22.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BOLT.

Bolt Biotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INAB	52 Neutral	$19.24M	-0.30	-189.72%	―	―	70.57%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BOLT	48 Neutral	$11.32M	-0.26	-81.97%	―	-46.88%	34.83%
XBIO	42 Neutral	$5.09M	-1.08	-57.43%	―	13.30%	22.70%
MBIO	42 Neutral	$7.04M	-0.76	-418.83%	―	―	98.58%
LYRA	41 Neutral	$3.16M	-0.07	-404.48%	―	-59.21%	68.97%